TPD52 and prostate cancer: Moreover, recent evidence indicates that PC-1/PrLZ is frequently overexpressed in advanced prostate cancer tissues [11], and this increased expression contributes to malignant phenotypes, including androgen-dependent and-independent growth, anchor-independent growth and tumorigenicity [12, 13].